

**UNITED STATES DISTRICT COURT
WESTERN DISTRICT OF TENNESSEE
WESTERN DIVISION**

NOVO NORDISK A/S AND NOVO
NORDISK INC.

Plaintiffs,

v.

PRO HEALTH INVESTMENTS, LLC,

Defendant.

Case No. _____

COMPLAINT

Plaintiffs Novo Nordisk A/S (“NNAS”) and Novo Nordisk Inc. (“NNI”) (collectively, “Plaintiffs” or “Novo Nordisk”), by and through their attorneys, file this complaint against Pro Health Investments, LLC (“Defendant”) for trademark infringement, false advertising and unfair competition and seek injunctive and other relief. Plaintiffs allege as follows, upon actual knowledge with respect to themselves and their own acts, and upon information and belief as to all other matters.

INTRODUCTION

1. Novo Nordisk is a healthcare company with a 100-year history of innovation in developing medicines to treat serious chronic diseases like diabetes and obesity.

2. The development of semaglutide is an example of Novo Nordisk’s commitment to innovation for people living with chronic diseases. Semaglutide is the foundational molecule which serves as the primary ingredient for Novo Nordisk’s three prescription-only medicines approved by the Food and Drug Administration (“FDA”): Wegovy[®] (semaglutide) injection 2.4

mg, for chronic weight management, and Ozempic[®] (semaglutide) injection 0.5 mg, 1 mg, or 2 mg and Rybelsus[®] (semaglutide) tablets 7 mg or 14 mg, both for adults with type 2 diabetes.

3. Novo Nordisk is the only company in the U.S. with FDA-approved products containing semaglutide. Novo Nordisk is also the only company authorized to identify its products containing semaglutide using the trademarks Wegovy[®], Ozempic[®], and Rybelsus[®]. The FDA has not approved any generic versions of semaglutide.

4. This is an action brought pursuant to the Lanham Act, 15 U.S.C. §§ 1051 et seq., related state laws and the common law, arising out of Defendant's infringement of Plaintiffs' rights in their Wegovy[®] mark and Defendant's acts of false advertising and unfair competition.

**Novo Nordisk's FDA-Approved Semaglutide Product,
Wegovy[®], and Registered Trademark**

5. Plaintiffs use the trademark "Wegovy" to identify and promote the FDA-approved drug, Wegovy[®]. Wegovy[®] is sold and marketed in the United States by NNAS's, indirect, wholly-owned subsidiary, NNI.

6. Wegovy[®] is indicated for chronic weight management in adults and children aged ≥ 12 years with obesity (BMI ≥ 30 for adults, BMI $\geq 95^{\text{th}}$ percentile for age and sex for children), or some adults with excess weight (BMI ≥ 27) (overweight) with weight-related medical problems, along with a reduced calorie meal plan and increased physical activity.

7. Wegovy[®] has a unique safety and efficacy profile which is detailed in its product label.

8. Wegovy[®] is a prescription-only medicine that should only be prescribed in direct consultation with, and under the supervision of, a licensed healthcare professional.

9. Wegovy[®] has been extensively studied in clinical trials and is FDA-approved.

10. Novo Nordisk does not sell its FDA-approved semaglutide product, Wegovy[®], to Defendant, for resale or redistribution.

11. Novo Nordisk first adopted and used the Wegovy[®] mark at least as early as 2021, and has used it continuously since that time. Novo Nordisk has extensively promoted, advertised and marketed its prescription-only medicine bearing the Wegovy[®] mark in many different channels, directed both to physicians and other health care professionals and to consumers.

12. As a result of its use of the Wegovy[®] mark, NNAS owns valuable common law rights in and to the Wegovy[®] mark.

**Defendant's Trademark Infringement and False Advertising
in Connection With its Sale to Patients of Unapproved Compounded Drugs**

13. Defendant markets and sells to patients compounded drug products that purport to contain semaglutide and that are not approved by the FDA (“Unapproved Compounded Drugs”).

14. On information and belief, the Unapproved Compounded Drugs sold by Defendant are made by compounding pharmacies, which deliver them to Defendant for administration or dispensing to patients.

15. The FDA defines compounding as a “practice in which a licensed pharmacist, a licensed physician, or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.” See <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding>.

16. According to the FDA, “[c]ompounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.”

17. The FDA has further stated that: “Compounded drugs . . . do not have the same safety, quality, and effectiveness assurances as approved drugs. Unnecessary use of compounded drugs unnecessarily exposes patients to potentially serious health risks. Because compounded drugs are not FDA-approved, FDA does not verify their safety, effectiveness or quality before they are marketed.”¹

18. On May 31, 2023, FDA issued guidance on “medications containing semaglutide marketed for Type 2 diabetes or weight loss,” which provides that: (1) “compounded drugs are not FDA-approved, and the agency does not verify the safety or effectiveness of compounded drugs”; and (2) “FDA has received adverse event reports after patients used compounded semaglutide. Patients should not use a compounded drug if an approved drug is available to treat a patient. Patients and health care professionals should understand that the agency does not review compounded versions of these drugs for safety, effectiveness, or quality.”

19. Defendant uses Novo Nordisk’s Wegovy[®] trademark to market and sell Unapproved Compounded Drugs purporting to contain “semaglutide” that is not Wegovy[®]. Defendant unlawfully uses Novo Nordisk’s trademark to attract customers and generate revenues and profits, including by passing off as Wegovy[®] its own Unapproved Compounded Drugs purporting to contain “semaglutide.”

20. Defendant first started using Novo Nordisk’s Wegovy[®] mark to advertise its Unapproved Compounded Drugs well after NNAS’s first use and registration of its Wegovy[®] mark.

¹ Compounding and the FDA: Questions and Answers, <https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>.

21. Defendant also falsely advertises its Unapproved Compounded Drugs on its website by making statements that describe Wegovy[®], but are false or misleading as to Defendant's Unapproved Compounded Drugs.

22. Defendant has made misleading statements in advertising and promotion that claim or imply that its Unapproved Compounded Drugs have been approved by FDA and/or have been subjected to clinical studies and trials.

23. Defendant continues to use the Wegovy[®] mark, including in advertising and promotion on its website and on its social media site viewed by its customers who, upon information and belief, are seeking to buy but are in fact not buying genuine Wegovy[®] products.

24. Defendant's prominent and misleading use of the Wegovy[®] mark is likely to cause consumers to falsely believe that they are actually purchasing genuine Wegovy[®] products, that Defendant is a source for Novo Nordisk's FDA-approved products, and/or that Defendant's services are provided, licensed, sponsored, authorized, or approved by Novo Nordisk.

25. Defendant's use of the Wegovy[®] mark is without the permission, consent or authorization of Novo Nordisk. Defendant has no right to use, and Defendant knows that it has no right to use, the Wegovy[®] mark in connection with Defendant's Unapproved Compounded Drugs or otherwise.

26. Novo Nordisk has no control over the nature, quality or efficacy of the products sold by Defendant, including the Unapproved Compounded Drugs.

THE PARTIES

27. Plaintiff NNAS is a corporation organized and existing under the laws of the Kingdom of Denmark and has its principal place of business in Bagsværd, Denmark.

28. Plaintiff NNI is a corporation organized and existing under the laws of Delaware and has its principal place of business in Plainsboro, New Jersey.

29. NNI promotes, offers, and/or sells Novo Nordisk's Wegovy[®] products throughout the United States, including in this District. NNAS has granted to NNI exclusive rights to market, advertise, promote, offer for sale and sell Wegovy[®] products in the United States.

30. Defendant is a corporation organized and existing under the laws of the State of Tennessee with a business address at 3445 Poplar Avenue, Suite 18, Memphis, Tennessee 38111, in this judicial district. Defendant sells and promotes Unapproved Compounded Drugs masquerading as Wegovy[®] and/or uses the Wegovy[®] mark in its advertising and promotion of Unapproved Compounded Drugs that are not Wegovy[®].

JURISDICTION AND VENUE

31. The Court has subject matter jurisdiction over the Lanham Act causes of action pleaded herein pursuant to 35 U.S.C. § 1121 and 28 U.S.C. § 1338(a). The Court has supplemental jurisdiction over the state and common law causes of action pleaded herein pursuant to 28 U.S.C. § 1338(b).

32. Venue is proper in this District pursuant to 28 U.S.C. § 1391 because Defendant operates in this District, manufactures and/or sells its Unapproved Compounded Drugs in this District, and otherwise conducts business in this District. Defendant is subject to personal jurisdiction in this District.

NOVO NORDISK'S WEGOVY[®] TRADEMARK

33. Plaintiff NNAS is the owner of (a) U.S. trademark registration number 6,585,492, issued on December 14, 2021, for the mark WEGOVY for pharmaceutical preparations, in International Class 5. A true and correct copy of Plaintiff's registration number 6,585,492 for the WEGOVY[®] mark is attached hereto as **Exhibit A**.

34. The Wegovy[®] trademark is inherently distinctive.

35. Novo Nordisk promotes and advertises its Wegovy[®] products through various channels, including on the websites wegovy.com and/or novonordisk-us.com, and to physicians and licensed healthcare professionals, among others.

36. As a result of Novo Nordisk's long use, promotion, and advertising of the Wegovy[®] trademark and products, the Wegovy[®] mark is exclusively associated with Plaintiffs, serves to identify genuine Novo Nordisk products, and is a valuable asset of Novo Nordisk.


37. As a result of Novo Nordisk's long use, promotion, and advertising of the Wegovy[®] trademark and products, the Wegovy[®] trademark is a well-known, strong and famous mark, and became famous prior to any of the acts of Defendant complained of herein.

DEFENDANT'S INFRINGING USE OF THE WEGOVY[®] MARK

38. Long after Novo Nordisk's first use of the Wegovy[®] mark at least as early as 2021, long after NNAS's priority date of 2020 for the Wegovy[®] trademark, and long after NNAS secured its federal registration for the Wegovy[®] mark in 2021, Defendant started using the Wegovy[®] mark in commercial advertising and promotion to promote its Unapproved Compounded Drugs in a false and misleading way. Examples of Defendant's trademark infringement and false advertising are shown below and attached hereto as **Exhibit B** (from Defendant's website) and **Exhibit C** (from Defendant's social media postings).

39. Defendant promotes its Unapproved Compounded Drugs on its website with messages such as "ARE YOU LOOKING FOR WEGOVY," "What is Wegovy?" and "Wegovy works by sending a message to your brain that says 'I am full. Stop eating.' On Wegovy, you'll feel fuller faster, so you'll eat less, resulting in weight loss. . . . Until now, this medicine has been difficult to obtain and very expensive. We are excited to announce that we now have it available for convenient access at a reasonable price."

40. The images below are true and correct representations of information on Defendant's website, <https://prohealthmemphis.com/>.



What is Wegovy?


Wegovy, also known as semaglutide, is a weekly injection approved by the FDA in 2021 for weight loss. It belongs to a class of drugs known as GLP-1 agonists which were originally developed to treat type 2 diabetes.

Wegovy works by sending a message to your brain that says, "I am full. Stop eating." On Wegovy, you'll feel fuller faster, so you'll eat less, resulting in weight loss. Results have been very promising. Until now, this medicine has been difficult to obtain and very expensive. We are excited to announce that we now have it available for convenient access at a reasonable price. If you are ready to lose weight and want to try the latest in weight loss medicine fully approved by the FDA then stop by or make an appointment online.

How does it work?

Wegovy slows down gastrointestinal motility, causing patients to feel full, and acts on the appetite centers in the brain to decrease hunger. In other words, people who use this type of medication are able to feel full with smaller portions and they are less hungry, which induces weight loss.

41. Defendant promotes its Unapproved Compounded Drugs on its social media website maintained on Facebook.com using similar messaging. The image below is a true and correct representation of information published on Facebook and available for viewing as of the date of the Complaint (similar infringing postings were made on May 17 and June 14, 2023).



42. Defendant's labels, advertising and promotional materials are false and misleading, suggesting and/or stating an association with Plaintiffs' FDA-approved Wegovy[®] products, when no such association exists.

43. There is no need for Defendant to use the Wegovy[®] trademark to advertise or promote its Unapproved Compounded Drugs purporting to contain "semaglutide," other than to trade upon the reputation of Plaintiffs and to create confusion in the marketplace and/or mislead the public regarding the origin, identity or source of Defendant's Unapproved Compounded Drugs.

44. Defendant's unauthorized use of the Wegovy[®] trademark is likely to cause confusion, to cause mistake, or to deceive, and infringes Plaintiffs' established exclusive rights in that trademark.

45. Upon information and belief, unless enjoined by this Court, Defendant will continue to use the Wegovy[®] mark and/or otherwise falsely advertise its products as associated with or being Wegovy[®], all in violation of Plaintiffs' rights.

FIRST CAUSE OF ACTION

(Trademark Infringement in Violation of 15 U.S.C. § 1114(1))

46. Plaintiff NNAS realleges and incorporates by reference each of the allegations contained in paragraphs 1-45 of this Complaint as though fully set forth here.

47. Plaintiff NNAS's Wegovy[®] mark is an inherently distinctive, strong, valid, and protectable trademark owned by Plaintiff NNAS.

48. Plaintiff NNAS's trademark registration for its Wegovy[®] mark constitutes *prima facie* evidence of the validity of the mark, of Plaintiff NNAS's registration and ownership of the mark, and of Plaintiff NNAS's exclusive right to use the mark in commerce on or in connection with the goods identified in the registration.

49. By virtue of its prior use and registration, Plaintiff NNAS has priority over Defendant with respect to the use of the Wegovy[®] mark for pharmaceutical preparations sold in the United States.

50. Defendant uses the Wegovy[®] mark in connection with the sale, advertising, and promotion of Unapproved Compounded Drugs purporting to contain semaglutide.

51. Defendant's use in commerce of the Wegovy[®] mark is likely to cause confusion, to cause mistake, or to deceive with respect to Plaintiff NNAS's identical mark.

52. The above-described acts of Defendant constitute infringement of a registered trademark in violation of Section 32(1) of the Lanham Act, 15 U.S.C. § 1114(1), entitling Plaintiff NNAS to relief.

53. Defendant has unfairly profited from its trademark infringement.

54. By reason of Defendant's acts of trademark infringement, Plaintiff NNAS has suffered damage to the goodwill associated with its mark.

55. Defendant's acts of trademark infringement have irreparably harmed and, if not enjoined, will continue to irreparably harm Plaintiff NNAS, its federally registered trademark and the valuable goodwill associated with that trademark.

56. Defendant's acts of trademark infringement have irreparably harmed, and if not enjoined, will continue to irreparably harm the interests of the public in being free from confusion, mistake, and deception.

57. By reason of Defendant's acts, Plaintiff NNAS's remedies at law are not adequate to compensate for the injuries inflicted by Defendant. Accordingly, Plaintiff NNAS is entitled to entry of preliminary and permanent injunctive relief pursuant to 15 U.S.C. § 1116.

58. By reason of Defendant's willful acts of trademark infringement, Plaintiff NNAS is entitled to treble damages under 15 U.S.C. § 1117.

59. This is an exceptional case, making Plaintiff NNAS eligible for an award of attorneys' fees under 15 U.S.C. § 1117.

SECOND CAUSE OF ACTION

(Trademark Infringement, Use of False Designation of Origin and Unfair Competition in Violation of 15 U.S.C. § 1125(a)(1)(A))

60. Plaintiffs reallege and incorporate by reference each of the allegations contained in paragraphs 1-45 of this Complaint as though fully set forth here.

61. Defendant uses the Wegovy[®] mark in commerce in connection with Defendant's goods and services and in commercial advertising and promotion of its goods and services.

62. Defendant uses the Wegovy[®] mark in commerce in a manner that is likely to cause confusion, or to cause mistake, or to deceive the relevant public into believing that Defendant's goods or services are authorized, sponsored, approved by, or otherwise affiliated with Plaintiffs, with Plaintiffs' genuine Wegovy[®] products, and/or with the Wegovy[®] mark.

63. The above-described acts of Defendant constitute infringement of the Wegovy[®] mark and use of false designations of origin in violation of Section 43(a)(1)(A) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(A), entitling Plaintiffs to relief.

64. Defendant has unfairly profited from the actions alleged.

65. By reason of the above-described acts of Defendant, Plaintiffs have suffered damage to the goodwill associated with the Wegovy[®] trademark.

66. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm Plaintiffs, the Wegovy[®] trademark, and the valuable goodwill associated with the trademark.

67. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm the interest of the public in being free from confusion, mistake, and deception.

68. By reason of Defendant's acts, Plaintiffs' remedies at law are not adequate to compensate for the injuries inflicted by Defendant. Accordingly, Plaintiffs are entitled to entry of preliminary and permanent injunctive relief pursuant to 15 U.S.C. § 1116.

69. Because the above-described acts of Defendant are willful, Plaintiffs are entitled to treble damages under 15 U.S.C. § 1117.

70. This is an exceptional case, making Plaintiffs eligible for an award of attorneys' fees under 15 U.S.C. § 1117.

THIRD CAUSE OF ACTION

**(Defendant's False and Misleading Advertising and Promotion
in Violation of 15 U.S.C. § 1125(a)(1)(B))**

71. Plaintiffs reallege and incorporate by reference each of the allegations contained in paragraphs 1-45 of this Complaint as though fully set forth here.

72. Defendant's practices, as described in this Complaint, constitute unfair competition and false advertising in violation of Section 43(a)(1)(B) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(B).

73. Defendant has violated the Lanham Act by using false or misleading descriptions of fact and false or misleading representations of fact in its commercial advertising or promotion that misrepresent the nature, characteristics, and/or qualities of Defendant's business practices and products, as set forth above.

74. Defendant has also engaged in other false or misleading advertising and promotion intended to assure consumers that Defendant's practices are lawful. Upon information and belief, Defendant provides consumers who purchase Defendant's Unapproved Compounded Drugs (or whom Defendant is trying to persuade to purchase its drugs) information that makes several false or misleading statements, including the below excerpt from Exhibit B:

What is Wegovy?

Wegovy, also known as semaglutide, is a weekly injection approved by the FDA in 2021 for weight loss. It belongs to a class of drugs known as GLP-1 agonists which were originally developed to treat type 2 diabetes.

Wegovy works by sending a message to your brain that says, "I am full. Stop eating." On Wegovy, you'll feel fuller faster, so you'll eat less, resulting in weight loss. Results have been very promising. Until now, this medicine has been difficult to obtain and very expensive. We are excited to announce that we now have it available for convenient access at a reasonable price. If you are ready to lose weight and want to try the latest in weight loss medicine fully approved by the FDA then stop by or make an appointment online.

75. Defendant makes the statement on its website: "if you are ready to lose weight and want to try the latest in weight loss medicine fully approved by the FDA then stop by or make an appointment online." This statement implies that Defendant's Unapproved Compounded Drugs are fully approved by FDA, which is false and misleading.

76. The above-described acts of Defendant, if not enjoined by this Court, are likely to deceive members of the general public.

77. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm Plaintiffs.

78. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm the interest of the public in being free from confusion, mistake, and deception.

79. By reason of Defendant's acts as alleged above, Plaintiffs have suffered and will continue to suffer injuries, including injury to Plaintiffs' business reputation. However, Plaintiffs' remedies at law are not adequate to compensate for all the injuries inflicted by Defendant. Accordingly, Plaintiffs are entitled to entry of preliminary and permanent injunctive relief requiring Defendant to cease its false and misleading advertising and promotion and unfair competitive practices.

FOURTH CAUSE OF ACTION

(Common Law Unfair Competition)

80. Plaintiffs reallege and incorporate by reference each of the allegations contained in paragraphs 1-45 of this Complaint as though fully set forth here.

81. The above-described acts of Defendant constitute common law unfair competition.

82. The above-described acts of Defendant unfairly and wrongfully exploit Plaintiffs' trademark, goodwill and reputation.

83. By reason of the above-described acts of Defendant, Plaintiffs have suffered damage to the goodwill associated with the Wegovy[®] trademark.

84. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm Plaintiffs and the Wegovy[®] trademark.

85. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm the interest of the public in being free from confusion, mistake, and deception.

86. By reason of Defendant's acts, Plaintiffs' remedies at law are not adequate to compensate for the injuries inflicted by Defendant. Accordingly, Plaintiffs are entitled to entry of preliminary and permanent injunctive relief, in addition to monetary relief in the form of disgorgement of Defendant's profits, and corrective advertising costs.

FIFTH CAUSE OF ACTION

(Violation of Tennessee Consumer Protection Act, Tenn. Code. Ann. § 47-18-101 et seq.)

87. Plaintiffs reallege and incorporate by reference each of the allegations contained in paragraphs 1-45 of this Complaint as though fully set forth here.

88. The above-described acts of Defendant constitute unfair and deceptive acts or practices in violation of the Tennessee Consumer Protection Act ("TCPA").

89. The TCPA prohibits “unfair or deceptive acts or practices affecting the conduct of any trade or commerce.” Tenn. Code Ann. § 47-18-104(a). The TCPA defines unfair or deceptive acts to include falsely passing off goods as those of another; causing likelihood of confusion as to the source, sponsorship or approval, or certification of goods or services; and causing likelihood of confusion as to affiliation, connection, or association with, or certification by, another. Tenn. Code Ann. § 47-18-104(b).

90. The above-described acts of Defendant are made in the conduct of Defendant’s business, trade or commerce, and are unfair and deceptive as defined by the TCPA, because Defendant is falsely passing off goods as those of Plaintiffs, causing likelihood of confusion as to the source, sponsorship, approval or certification of its goods, and causing likelihood of confusion as to affiliation, connection, or association with, or certification/approval of its goods by Plaintiffs and/or the FDA.

91. Defendant’s unfair and deceptive acts or practices affect the conduct of trade or commerce within Tennessee.

92. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm Plaintiffs and the trademark.

93. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm the interest of the public in being free from confusion, mistake, and deception.

94. By reason of the above-described acts of Defendant, Plaintiffs have suffered an ascertainable loss, including damage to the goodwill associated with its trademark.

95. Defendant has unfairly profited from the actions alleged.

96. By reason of Defendant's acts, Plaintiffs' remedy at law is not adequate to compensate for the injuries inflicted by Defendant. Accordingly, Plaintiffs are entitled to entry of preliminary and permanent injunctive relief, in addition to monetary relief in the form of disgorgement of Defendant's profits, and corrective advertising costs.

REQUEST FOR RELIEF

WHEREFORE, Plaintiffs request judgment against Defendant as follows:

1. That the Court enter a judgment against Defendant that Defendant has:
 - a. Infringed the rights of Plaintiff NNAS in its federally registered Wegovy[®] mark, in violation of 15 U.S.C. § 1114(1);
 - b. Infringed the rights of Plaintiffs in the Wegovy[®] mark and engaged in unfair competition, in violation of 15 U.S.C. § 1125(a);
 - c. Engaged in false and misleading advertising and promotion, in violation of 15 U.S.C. § 1125(a);
 - d. Engaged in unfair competition under the common law of Tennessee and the Tennessee Consumer Protection Act.
2. That each of the above acts was willful.
3. That the Court preliminarily and permanently enjoin and restrain Defendant and its agents, servants, employees, successors and assigns, and all other persons acting in concert with or in conspiracy with or affiliated with Defendant, from:
 - a. Using the trademark Wegovy[®], or any marks, names or designations confusingly similar to it, in connection with the advertising, promoting, marketing, selling or offering for sale of any goods or services (including, but not limited to, Unapproved Compounded Drugs) or otherwise engaging in any activity that is likely to cause confusion, cause mistake or deceive or otherwise

infringes any rights of Plaintiffs in and to the Wegovy[®] mark or any similar marks;

- b. Falsely stating or suggesting that any Unapproved Compounded Drugs are genuine Wegovy[®] products, that Defendant is associated or connected in any way with Plaintiffs or Plaintiffs' products, or that Defendant's Unapproved Compounded Drugs are approved by the FDA;
- c. Falsely stating or suggesting that Defendant's Unapproved Compounded Drugs have been proven to achieve certain therapeutic results or effects;
- d. Engaging in any unfair competition with Plaintiffs; and/or
- e. Engaging in any deceptive acts or practices.

4. Requiring Defendant, its agents, servants, employees, successors and assigns, and all other persons acting in concert with or in conspiracy with or affiliated with Defendant, to engage in corrective advertising by informing consumers that Defendant is not and never has been authorized, affiliated, sponsored, approved, or related to Plaintiffs or genuine Wegovy[®] products and that Defendant's Unapproved Compounded Drugs are not and have never been genuine Wegovy[®] products or approved by the FDA.

5. That Plaintiffs be awarded monetary relief in the form of disgorgement of Defendant's profits for Defendant's trademark infringement, false advertising and unfair competition and that this monetary relief be trebled due to Defendant's willfulness, in accordance with the provisions of 15 U.S.C. § 1117 and any applicable state laws.

6. That Plaintiffs be awarded all Defendant's profits resulting from Defendant's infringement of Plaintiffs' rights and by means of Defendant's unfair competition.

7. That Defendant be ordered to account for and disgorge to Plaintiffs all amounts by which Defendant has been unjustly enriched by reason of Defendant's unlawful actions.
8. That Plaintiffs be awarded punitive damages by reason of Defendant's willful unlawful actions.
9. For pre-judgment and post-judgment interest on all damages.
10. That the Court award Plaintiffs their reasonable attorneys' fees pursuant to 15 U.S.C. § 1117, the Tennessee Consumer Protection Act and any other applicable provision of law.
11. That the Court award Plaintiffs the costs of suit incurred herein.
12. For such other or further relief as the Court may deem just and proper.

DATED: June 20, 2023

Respectfully submitted,

s/ Steven A. Riley

Steven A. Riley (TN Bar No. 6258)

Milton S. McGee, III (TN Bar No. 24150)

RILEY & JACOBSON, PLC

1906 West End Ave.

Nashville, TN 37203

(615) 320-3700

sriley@rjfirm.com

tmcgee@rjfirm.com

Aaron S. Craig (Pro hac vice application
forthcoming)

Joseph N. Akrotirianakis (Pro hac vice application
forthcoming)

KING & SPALDING LLP

633 West Fifth Street

Suite 1600

Los Angeles, CA 90071

(213) 443-4355

acraig@kslaw.com

jakro@kslaw.com

Bruce W. Baber (Pro hac vice application
forthcoming)
KING & SPALDING LLP
1180 Peachtree Street, NE, Suite 1600
Atlanta, GA 30309-3521
(404) 572-4600
bbaber@kslaw.com

*Attorneys for Plaintiffs NOVO NORDISK A/S and
NOVO NORDISK INC.*

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

I. (a) PLAINTIFFS

Novo Nordisk A/S and Novo Nordisk Inc.

(b) County of Residence of First Listed Plaintiff Hovedstaden, Denmark (EXCEPT IN U.S. PLAINTIFF CASES)

(c) Attorneys (Firm Name, Address, and Telephone Number) Steven A. Riley and Milton S. McGee, III Riley & Jacobson, PLC, 1906 West End Ave, Nashville, TN 37203 (615-320-3700); see attachment

DEFENDANTS

Pro Health Investments, LLC

County of Residence of First Listed Defendant Shelby County (IN U.S. PLAINTIFF CASES ONLY)

NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.

Attorneys (If Known)

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)

- 1 U.S. Government Plaintiff, 2 U.S. Government Defendant, 3 Federal Question (U.S. Government Not a Party), 4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)

Table with columns for Plaintiff (PTF) and Defendant (DEF) citizenship and business location (Citizen of This State, Citizen of Another State, Citizen or Subject of a Foreign Country, Incorporated or Principal Place of Business In This State, Incorporated and Principal Place of Business In Another State, Foreign Nation).

IV. NATURE OF SUIT (Place an "X" in One Box Only)

Large table with categories: CONTRACT, REAL PROPERTY, CIVIL RIGHTS, TORTS, PRISONER PETITIONS, FORFEITURE/PENALTY, LABOR, IMMIGRATION, BANKRUPTCY, SOCIAL SECURITY, FEDERAL TAX SUITS, OTHER STATUTES.

V. ORIGIN (Place an "X" in One Box Only)

- 1 Original Proceeding, 2 Removed from State Court, 3 Remanded from Appellate Court, 4 Reinstated or Reopened, 5 Transferred from Another District (specify), 6 Multidistrict Litigation - Transfer, 8 Multidistrict Litigation - Direct File

VI. CAUSE OF ACTION

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity): 15 U.S.C. § 1114, 15 U.S.C. § 1125

Brief description of cause: Trademark Infringement

VII. REQUESTED IN COMPLAINT:

CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P. DEMAND \$

CHECK YES only if demanded in complaint: JURY DEMAND: Yes No

VIII. RELATED CASE(S) IF ANY

(See instructions):

JUDGE DOCKET NUMBER

DATE 06/20/2023 SIGNATURE OF ATTORNEY OF RECORD s/Steven A. Riley

FOR OFFICE USE ONLY

RECEIPT # AMOUNT APPLYING IFP JUDGE MAG. JUDGE

**UNITED STATES DISTRICT COURT
WESTERN DISTRICT OF TENNESSEE
WESTERN DIVISION**

NOVO NORDISK A/S AND NOVO
NORDISK INC.

Plaintiffs,

v.

PRO HEALTH INVESTMENTS, LLC,

Defendant.

Case No. _____

**ADDENDUM TO JS-44: ATTORNEYS OF RECORD FOR PLAINTIFFS NOVO
NORDISK A/S AND NOVO NORDISK INC.**

Attorneys of record:

Aaron S. Craig
(*Pro hac vice application forthcoming*)
Joseph N. Akrotirianakis
(*Pro hac vice application forthcoming*)
633 West Fifth Street, Suite 1600
Los Angeles, CA 90071
(213) 443-4355
acraig@kslaw.com
jakro@kslaw.com

Bruce W. Baber
(*Pro hac vice application forthcoming*)
1180 Peachtree Street, NE, Suite 1600
Atlanta, GA 30309-3521
(404) 572-4600
bbaber@kslaw.com

AO 440 (Rev. 06/12) Summons in a Civil Action

UNITED STATES DISTRICT COURT

for the

Western District of Tennessee

Novo Nordisk A/S and Novo Nordisk Inc.

Plaintiff(s)

v.

Pro Health Investments, LLC

Defendant(s)

Civil Action No.

SUMMONS IN A CIVIL ACTION

To: (Defendant's name and address) Pro Health Investments, LLC
c/o Estes Folk, agent for service of process
3445 Poplar Ave
Suite 18
Memphis, TN 38111-4667

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are: Steven A. Riley, Milton S. McGee, III, Riley & Jacobson, PLC, 1906 West End Ave, Nashville, TN 37203

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date:

Signature of Clerk or Deputy Clerk

AO 440 (Rev. 06/12) Summons in a Civil Action (Page 2)

Civil Action No. _____

PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))

This summons for *(name of individual and title, if any)* _____
was received by me on *(date)* _____ .

I personally served the summons on the individual at *(place)* _____
_____ on *(date)* _____ ; or

I left the summons at the individual's residence or usual place of abode with *(name)* _____
_____, a person of suitable age and discretion who resides there,
on *(date)* _____ , and mailed a copy to the individual's last known address; or

I served the summons on *(name of individual)* _____ , who is
designated by law to accept service of process on behalf of *(name of organization)* _____
_____ on *(date)* _____ ; or

I returned the summons unexecuted because _____ ; or

Other *(specify)*: _____

My fees are \$ _____ for travel and \$ _____ for services, for a total of \$ _____ 0.00 _____ .

I declare under penalty of perjury that this information is true.

Date: _____

Server's signature

Printed name and title

Server's address

Additional information regarding attempted service, etc:

REQUIREMENTS TO MAINTAIN YOUR FEDERAL TRADEMARK REGISTRATION

WARNING: YOUR REGISTRATION WILL BE CANCELLED IF YOU DO NOT FILE THE DOCUMENTS BELOW DURING THE SPECIFIED TIME PERIODS.

Requirements in the First Ten Years*

What and When to File:

- **First Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) between the 5th and 6th years after the registration date. See 15 U.S.C. §§1058, 1141k. If the declaration is accepted, the registration will continue in force for the remainder of the ten-year period, calculated from the registration date, unless cancelled by an order of the Commissioner for Trademarks or a federal court.
- **Second Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between the 9th and 10th years after the registration date.* See 15 U.S.C. §1059.

Requirements in Successive Ten-Year Periods*

What and When to File:

- You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between every 9th and 10th-year period, calculated from the registration date.*

Grace Period Filings*

The above documents will be accepted as timely if filed within six months after the deadlines listed above with the payment of an additional fee.

***ATTENTION MADRID PROTOCOL REGISTRANTS:** The holder of an international registration with an extension of protection to the United States under the Madrid Protocol must timely file the Declarations of Use (or Excusable Nonuse) referenced above directly with the United States Patent and Trademark Office (USPTO). The time periods for filing are based on the U.S. registration date (not the international registration date). The deadlines and grace periods for the Declarations of Use (or Excusable Nonuse) are identical to those for nationally issued registrations. See 15 U.S.C. §§1058, 1141k. However, owners of international registrations do not file renewal applications at the USPTO. Instead, the holder must file a renewal of the underlying international registration at the International Bureau of the World Intellectual Property Organization, under Article 7 of the Madrid Protocol, before the expiration of each ten-year term of protection, calculated from the date of the international registration. See 15 U.S.C. §1141j. For more information and renewal forms for the international registration, see <http://www.wipo.int/madrid/en/>.

NOTE: Fees and requirements for maintaining registrations are subject to change. Please check the USPTO website for further information. With the exception of renewal applications for registered extensions of protection, you can file the registration maintenance documents referenced above online at <http://www.uspto.gov>.

NOTE: A courtesy e-mail reminder of USPTO maintenance filing deadlines will be sent to trademark owners/holders who authorize e-mail communication and maintain a current e-mail address with the USPTO. To ensure that e-mail is authorized and your address is current, please use the Trademark Electronic Application System (TEAS) Correspondence Address and Change of Owner Address Forms available at <http://www.uspto.gov>.

BOOK AN IV +

SEE THE NURSE +

BOOK A SHOT +

MEMBERSHIPS +

OUR COVID STATEMENT

ARE YOU LOOKING FOR WEGOVIY?

GET STARTED WITH SEMAGLUTIDE INJECTIONS TODAY!

MAKE AN APPOINTMENT

GET MORE INFO

COMING SOON!!

PRO HEALTH COLLIERVILLE, PRO HEALTH SOUTHAVEN,
& PRO HEALTH BARTLETT

BECOME A HEALTH PRO.

LEARN MORE

PRO HEALTH HAS A FULL SPECTRUM OF WELLNESS SERVICES



MEMBER BENEFITS

Available monthly memberships



IV INFUSIONS

Top facility in Memphis



WALK IN SICK VISITS

No appointment needed



TESTOSTERONE THERAPY

Voted "Memphis Most"



WEIGHT LOSS

Evidence based Program



SINUS COCKTAIL

End sinus problems today

ARE YOU LOOKING FOR
WEGOVIY?


[LEARN MORE](#)

Let us introduce ourselves...

MEMPHIS' MOST CONVENIENT WELLNESS CLINIC

We opened in 2016 with the belief that the Memphis community needed a clinic offering both traditional and innovative wellness treatments under one roof just like in other big cities. Right now we are accomplishing this by providing IV hydration therapy, testosterone replacement, weight loss medications, and the sinus cocktail shot among other popular services like the Lipo shot, Myers' Cocktail, and high dose glutathione infusions. Don't forget to come to us for all of your sick visit needs as well. We are unique in that we actually dispense and administer most of the medicine prescribed on-site saving patients an added cost at the pharmacy. We are a no-wait, no-hassle place where the staff is friendly and the service is quick and professional. Make an appointment below or just come in today to see for yourself!





EVERYBODY'S MARATHON IS DIFFERENT.

Optimal health begins with hydration. No matter what you're recovering from, our IV Hydration Therapy will get you back up and running in no time.

[BOOK AN IV TODAY](#)

Customer Reviews

5 ★★★★★ based on 735 reviews

★★★★★ Kelly A. on 6/7/2023

★★★★★ Artie B. on 6/6/2023
Friendly and knowledgeable staff 😊

★★★★★ Morgan C. on 6/6/2023

★★★★★ Frankie S. on 6/5/2023

★★★★★ Christi D. on 6/4/2023

[More](#)

Powered by
 mindbody
business



**3445 Poplar Ave #18
Memphis, TN 38111**

901-417-6551
info@prohealthmemphis.com

1213 Ridgeway #104

Memphis, TN 38119

901-509-8205
info@prohealthmemphis.com

hours for both locations

Monday-Friday: 7:00-6:00

Saturday: 9:00-2:00

Sunday: By appointment

info@prohealthmemphis.com

Welcome to Pro Health Clinic

Let me make your appointment or

Southaven Location

Comer Village Loc

answer your questions...just ask me!

Coming Soon!

Coming Soon!

[Click here to get started](#) 🍷



BOOK AN IV +

SEE THE NURSE +

BOOK A SHOT +

MEMBERSHIPS +

OUR COVID STATEMENT

ARE YOU LOOKING FOR WEGOVY?

MAKE AN APPOINTMENT

FOR MORE INFO AND TO DISCUSS WITH A HEALTH PRO,
COMPLETE THE FORM BELOW...

Email

Phone

SUBMIT

GET STARTED WITH SEMAGLUTIDE TREATMENTS TODAY!

What is Wegovy?

Wegovy, also known as semaglutide, is a weekly injection approved by the FDA in 2021 for weight loss. It belongs to a class of drugs known as GLP-1 agonists which were originally developed to treat type 2 diabetes.

Wegovy works by sending a message to your brain that says, "I am full. Stop eating." On Wegovy, you'll feel fuller faster, so you'll eat less, resulting in weight loss. Results have been very promising. Until now, this medicine has been difficult to obtain and very expensive. We are excited to announce that we now have it available for convenient access at a reasonable price. If you are ready to lose weight and want to try the latest in weight loss medicine fully approved by the FDA then stop by or make an appointment online.

How does it work?

Wegovy slows down gastrointestinal motility, causing patients to feel full, and acts on the appetite centers in the brain to decrease hunger. In other words, people who use this type of medication are able to feel full with smaller portions and they are less hungry, which induces weight loss.

READY TO GET STARTED ON SEMAGLUTIDE?

Email

Phone

SUBMIT

Customer Reviews

5 ★★★★★ based on 735 reviews

★★★★★ Kelly A. on 6/7/2023

★★★★★ Artie B. on 6/6/2023
Friendly and knowledgeable staff 😊

★★★★★ Morgan C. on 6/6/2023

★★★★★ Frankie S. on 6/5/2023

★★★★★ Christi D. on 6/4/2023

More

Powered by




3445 Poplar Ave #18
Memphis, TN 38111

901-417-6551
info@prohealthmemphis.com

Southaven Location

Coming Soon!

1213 Ridgeway #104
Memphis, TN 38119

901-509-8205
info@prohealthmemphis.com

Collierville Location

Coming Soon

hours for both locations
Monday-Friday: 7:00-6:00
Saturday: 9:00-2:00
Sunday: By appointment
info@prohealthmemphis.com

Welcome to Pro Health Clinic
Let me make your appointment or
answer your questions...just ask me!

Click here to get started 🙌





prohealthmemphis • Follow



Looking for Wegovy? You're in luck! Visit <https://prohealthmemphis.com/> to get started today! Link in bio.

#memphis #choose901 #ilovememphis #ivhydration #ivtherapy #hydration #ivdrip #recovery #ivvitamintherapy #vitamindrip #wellness #vitamins #vitamininfusion #vitamintherapy #mobileiv #miami #resetiv #ivdrips #ivhydrationtherapy #iv #health #ivnurse #vegasheat #rejuvenating #replenish #nurselife #nursesrock #rn #nurses #recoverfaster

15w



Liked by gingerjuliehollis and others

FEBRUARY 21



Add a comment...

Post



prohealthmemphis • Follow



The search for Wegovy is over! Fill out the form to get started today at <https://prohealthmemphis.com/>. Link in bio.

#memphis #choose901 #ilovememphis #ivhydration #ivtherapy #hydration #ivdrip #recovery #ivvitamintherapy #vitamindrip #wellness #vitamins #vitamininfusion #vitamintherapy #mobileiv #miami #resetiv #ivdrips #ivhydrationtherapy #iv #health #ivnurse #vegasheat #rejuvenating #replenish #nurselife #nursesrock #rn #nurses #recoverfaster

5w



Liked by kakytucker and others

APRIL 28




Add a comment...

Post



prohealthmemphis • Follow



IS WEGOVY RIGHT FOR YOU?



prohealthmemphis Why Wegovy? Wegovy is a semaglutide injection that works to send messages to your brain telling you that you're full. This has had promising results in weight loss and we are so happy to provide our patients this service, right here in our clinic. Sign up for Wegovy today at <https://prohealthmemphis.com/>. Link in bio.

#memphis #choose901 #ilovememphis #ivhydration #ivtherapy #hydration #ivdrip #recovery #ivvitamintherapy #vitamindrip #wellness #vitamins #vitamininfusion #vitamintherapy #mobileiv #miami #resetiv #ivdrips #ivhydrationtherapy #iv #health #ivnurse #vegasheat #rejuvenating #replenish #nurselife #nursesrock #rn #nurses #recoverfaster

20w



Liked by **gingerjuliehollis** and others

JANUARY 18



Add a comment...


Post



prohealthmemphis • Follow



WE'VE GOT WEGOVY!



Looking for Wegovy? Look no further – we got it! Get started with your injections today at <https://prohealthmemphis.com/>. Link in bio.

#memphis #choose901 #ilovememphis #ivhydration #ivtherapy #hydration #ivdrip #recovery #ivvitamintherapy #vitamindrip #wellness #vitamins #vitamininfusion #vitamintherapy #mobileiv #miami #resetiv #ivdrips #ivhydrationtherapy #iv #health #ivnurse #vegasheat #rejuvenating #replenish #nurselife #nursesrock #rn #nurses #recoverfaster

27w



Liked by **audreystimpson** and others


NOVEMBER 29, 2022



Add a comment...

Post

**WE'VE
GOT
WEGOVY**



prohealthmemphis • Follow



prohealthmemphis Looking for Wegovy? We got it! Head over and fill out a form at <https://prohealthmemphis.com/> to get started and learn more. Link in bio.

39w



kelly_wilson_04 Dm on @MiamiVibes.mag 3M 🌴

39w Reply



prohealthmemphis #memphis #choose901 #ilovememphis #ivhydration #ivtherapy #hydration #ivdrip #recovery #ivvitamintherapy #vitamindrip #wellness #vitamins #vitamininfusion #vitamintherapy #mobileiv #miami #resetiv #ivdrips #ivhydrationtherapy #iv #health #ivnurse #vegasheat #rejuvenating #replenish #nurselife #nursesrock #rn #nurses #recoverfaster

39w Reply



Liked by **kndoster** and others

SEPTEMBER 7, 2022



Add a comment...

Post



prohealthmemphis • Follow



prohealthmemphis Looking for Wegovy? You're in luck! Visit <https://prohealthmemphis.com/> to get started today! Link in bio.

#memphis #choose901 #ilovememphis #ivhydration #ivtherapy #hydration #ivdrip #recovery #ivvitamintherapy #vitamindrip #wellness #vitamins #vitamininfusion #vitamintherapy #mobileiv #miami #resetiv #ivdrips #ivhydrationtherapy #iv #health #ivnurse #vegasheat #rejuvenating #replenish #nurselife #nursesrock #rn #nurses #recoverfaster

3w



Liked by janefolkmemphis and others

MAY 17



Add a comment...

Post



prohealthmemphis • Follow



GOT WEIGHT LOSS GOALS?



VISIT US FOR A BOOST!



prohealthmemphis Have big goals? We have a plan for you! At Pro Health, we offer a ton of effective weightloss services such as appetite suppressants, Wegovy and peptide therapy. Ready to get started? Visit <https://prohealthmemphis.com/> for more. Link in bio.

42w



prohealthmemphis #memphis #choose901 #ilovememphis #ivhydration #ivtherapy #hydration #ivdrip #recovery #ivvitamintherapy #vitamindrip #wellness #vitamins #vitamininfusion #vitamintherapy #mobileiv #miami #resetiv #ivdrips #ivhydrationtherapy #iv #health #ivnurse #vegasheat #rejuvenating #replenish #nurselife #nursesrock #rn #nurses #recoverfaster

42w Reply



Liked by **newdaymemphis** and others

AUGUST 17, 2022



Add a comment...

Post

IS **WEGOVY**
RIGHT
FOR YOU?



 **prohealth**
CLINIC



prohealthmemphis • Follow



Looking for Wegovy? We got it!! Start your weight loss journey today by signing up on our website, <https://prohealthmemphis.com/>. Link in bio.

43w



#memphis #choose901 #ilovememphis #ivhydration #ivtherapy #hydration #ivdrip #recovery #ivvitamintherapy #vitamindrip #wellness #vitamins #vitamininfusion #vitamintherapy #mobileiv #miami #resetiv #ivdrips #ivhydrationtherapy #iv #health #ivnurse #vegasheat #rejuvenating #replenish #nurselife #nursesrock #rn #nurses #recoverfaster

43w Reply




Liked by **ericaefant** and others

AUGUST 9, 2022



Add a comment...

Post



WE'RE
WEIGHT
LOSS
PROS

 **prohealth**
CLINIC



prohealthmemphis • Follow



prohealthmemphis Appetite suppressants are a great and effective tool to help aid your weight loss journey. At Pro Health, we not only offer appetite suppressants as a weight loss service but also B12 shots, Lipo-plex, Wegovy and more. Stop by and chat with a nurse today to see if you are a good candidate. Learn more at <https://prohealthmemphis.com/>. Link in bio.

38w



prohealthmemphis #memphis #choose901 #ilovememphis #ivhydration #ivtherapy #hydration #ivdrip #recovery #ivvitamintherapy #vitamindrip #wellness #vitamins #vitamininfusion #vitamintherapy #mobileiv #miami #resetiv #ivdrips #ivhydrationtherapy #iv #health #ivnurse #vegasheat #rejuvenating #replenish #nurselife #nursesrock #rn #nurses #recoverfaster



38w 1 like Reply



Liked by miccydenise and others


SEPTEMBER 15, 2022



Add a comment...

Post

START YOUR WEIGHT LOSS JOURNEY AT



prohealthmemphis • Follow



prohealthmemphis Are you thinking about starting your weight loss journey? We are SO proud of you! Allow us to guide you toward your goals with our advice, highly-sought after services such as Wegovy and constant support. Visit <https://prohealthmemphis.com/> for more. Link in bio.

32w



gym168w WoW send pic on @the_world_captures



32w Reply



prohealthmemphis #memphis #choose901 #ilovememphis #ivhydration #ivtherapy #hydration #ivdrip #recovery #ivvitamintherapy #vitamindrip #wellness #vitamins #vitamininfusion #vitamintherapy #mobileiv #miami #resetiv #ivdrips #ivhydrationtherapy #iv #health #ivnurse #vegasheat #rejuvenating #replenish #nurselife #nursesrock #rn #nurses #recoverfaster



32w Reply



Liked by yvette_jane_paxton_rhoton and others

OCTOBER 26, 2022



Add a comment...

Post

Interested in starting your Wegovy journey? We can kickstart your journey right here at Pro Health! Learn more and sign up today at

LOOKING FOR WEGOVY?



PROHEALTHMEMPHIS.COM

[HOMEPAGE](#) | Pro Health Wellness Clinic

[HOMEPAGE](#) | Weight Loss, Testosterone Replacement, Sinus Cocktails, Sick ...

[Learn more](#)



**UNITED STATES DISTRICT COURT
WESTERN DISTRICT OF TENNESSEE
WESTERN DIVISION**

NOVO NORDISK A/S AND NOVO
NORDISK INC.

Plaintiffs,

v.

PRO HEALTH INVESTMENTS, LLC,

Defendant.

Case No. _____

**PLAINTIFF NOVO NORDISK A/S'S
CORPORATE DISCLOSURE STATEMENT**

Pursuant to Fed. R. Civ. P. 7.1, Plaintiff, Novo Nordisk A/S, makes the following disclosures:

NNAS is a publicly traded corporation headquartered in Bagsværd, Denmark. No publicly held company owns 10% or more of the stock of NNAS.

NNAS's corporate parent is Novo Holdings A/S. Novo Holdings A/S is wholly owned by Novo Nordisk Foundation, a privately held entity.

Respectfully submitted,

s/ Steven A. Riley

Steven A. Riley (TN Bar No. 6258)
Milton S. McGee, III (TN Bar No. 24150)
RILEY & JACOBSON, PLC
1906 West End Ave.
Nashville, TN 37203
(615) 320-3700
sriley@rjfirm.com
tmcgee@rjfirm.com

Aaron S. Craig (Pro hac vice application
forthcoming)
Joseph N. Akrotirianakis (Pro hac vice application
forthcoming)
KING & SPALDING LLP
633 West Fifth Street
Suite 1600
Los Angeles, CA 90071
(213) 443-4355
acraig@kslaw.com
jakro@kslaw.com

Bruce W. Baber (Pro hac vice application
forthcoming)
KING & SPALDING LLP
1180 Peachtree Street, NE, Suite 1600
Atlanta, GA 30309-3521
(404) 572-4600
bbaber@kslaw.com

*Attorneys for Plaintiffs Novo Nordisk A/S and
Novo Nordisk Inc.*

CERTIFICATE OF SERVICE

I hereby certify that a true and correct copy of the foregoing document was provided to a private process server for personal service on the following and also sent via U.S. Certified Mail (with return receipt requested) on the 20th day of June 2023 to the following:

Estes Folk
3445 Poplar Ave
Suite 18
Memphis, TN 38111-4667

Registered Agent for Defendant

s/ Steven A. Riley _____

**UNITED STATES DISTRICT COURT
WESTERN DISTRICT OF TENNESSEE
WESTERN DIVISION**

NOVO NORDISK A/S AND NOVO
NORDISK INC.

Plaintiffs,

v.

PRO HEALTH INVESTMENTS, LLC,

Defendant.

Case No. _____

**PLAINTIFF NOVO NORDISK INC.’S
CORPORATE DISCLOSURE STATEMENT**

Pursuant to Fed. R. Civ. P. 7.1, Plaintiff, Novo Nordisk Inc., makes the following disclosures:

Novo Nordisk Inc. (“NNI”), by and through undersigned counsel, makes the following disclosures pursuant to Federal Rule of Civil Procedure 7.1:

NNI is a privately held corporation wholly owned by Novo Nordisk US Commercial Holdings, Inc.

Novo Nordisk US Commercial Holdings, Inc. is a privately held corporation wholly owned by Novo Nordisk US Holdings, Inc.

Novo Nordisk US Holdings, Inc. is a privately held corporation wholly owned by Novo Nordisk A/S (“NNAS”).

NNAS is a publicly traded corporation headquartered in Bagsværd, Denmark. No publicly held company owns 10% or more of the stock of NNAS.

NNAS’s corporate parent is Novo Holdings A/S. Novo Holdings A/S is wholly owned by Novo Nordisk Foundation, a privately held entity.

Respectfully submitted,

s/ Steven A. Riley

Steven A. Riley (TN Bar No. 6258)
Milton S. McGee, III (TN Bar No. 24150)
RILEY & JACOBSON, PLC
1906 West End Ave.
Nashville, TN 37203
(615) 320-3700
sriley@rjfirm.com
tmcgee@rjfirm.com

Aaron S. Craig (Pro hac vice application
forthcoming)
Joseph N. Akrotirianakis (Pro hac vice application
forthcoming)
KING & SPALDING LLP
633 West Fifth Street
Suite 1600
Los Angeles, CA 90071
(213) 443-4355
acraig@kslaw.com
jakro@kslaw.com

Bruce W. Baber (Pro hac vice application
forthcoming)
KING & SPALDING LLP
1180 Peachtree Street, NE, Suite 1600
Atlanta, GA 30309-3521
(404) 572-4600
bbaber@kslaw.com

*Attorneys for Plaintiffs Novo Nordisk A/S and
Novo Nordisk Inc.*

CERTIFICATE OF SERVICE

I hereby certify that a true and correct copy of the foregoing document was provided to a private process server for personal service on the following and also sent via U.S. Certified Mail (with return receipt requested) on the 20th day of June 2023 to the following:

Estes Folk
3445 Poplar Ave
Suite 18
Memphis, TN 38111-4667

Registered Agent for Defendant

s/ Steven A. Riley _____